Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.
Liu E, et al.
Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.
Neurology. 2015.
PMID: 26208959
Free PMC article.
Clinical Trial.
OBJECTIVE: To evaluate the effects of bapineuzumab on brain beta-amyloid (Abeta) burden using (11)C-Pittsburgh compound B ((11)C-PiB)-PET. ...Bapineuzumab, an anti-Abeta monoclonal antibody, or placebo, was administered by IV infusion every 13 weeks for 78 weeks. PET subst …
OBJECTIVE: To evaluate the effects of bapineuzumab on brain beta-amyloid (Abeta) burden using (11)C-Pittsburgh compound B ((11)C-PiB) …